Study of novel immunomodulators as monotherapy and in combination with anticancer agents in participants with advanced Hepatobiliary Cancer

Trial Identifier: D7987C00001
Sponsor: AstraZeneca
Start Date: April 2023
Primary Completion Date: December 2025
Study Completion Date: December 2026
Condition: Liver Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100050
CN Beijing, CN, 100142
CN Beijing, CN, 101100
CN Chengdu, CN, 610000
CN Chengdu, CN, 610041
CN Chongqing, CN, 400030
CN Fuzhou, CN, 350007
CN Guangzhou, CN, 510515
CN Guangzhou, CN, 510060
CN Harbin, CN, 150081
CN Hefei, CN, 230001
CN Hefei, CN, 230601
CN Hefei, CN, 230022
CN Nanning, CN, 530021
CN Shanghai, CN, 200032
ES Barcelona, ES, 8035
ES Barcelona, ES, 08036
ES Madrid, ES, 28007
ES Madrid, ES, 28040
ES Pamplona, ES, 31008
GB Cambridge, GB, CB2 0QQ
GB LONDON, GB, NW3 2QG
GB Manchester, GB, M20 4BX
HK Hong Kong, HK, 999077
HK Shatin, HK, 00000
IT Firenze, IT, 50134
IT Milano, IT, 20132
IT Napoli, IT, 80131
IT Rozzano, IT, 20089
JP Chuo-ku, JP, 104-0045
JP Kashiwa, JP, 277-8577
JP Yokohama-shi, JP, 241-8515
KR Seongnam-Si, KR, 463-712
KR Seoul, KR, 06351
KR Seoul, KR, 05505
KR Seoul, KR, 03722
KR Seoul, KR, 03080
TW Kaohsiung, TW, 80756
TW Kaohsiung city, TW, 833
TW Liuying, TW, 736
TW Taichung, TW, 40705
TW Tainan City, TW, 70403
TW Taipei, TW, 10002
TW Taipei, TW, 11259
TW Taoyuan, TW, 333
US, AL Birmingham, AL, US, 35233
US, CA Los Angeles, CA, US, 90089
US, CA Orange, CA, US, 92868
US, KS Kansas City, KS, US, 66103
US, NY New York, NY, US, 10065